Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy - Summary - MDSpire

Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy

  • By

  • Rinki Deo

  • Manish C Choudhary

  • Owen T Glover

  • Rachel Bender Ignacio

  • Julie Boucau

  • Kara W Chew

  • Carlee Moser

  • Judith S Currier

  • Joseph J Eron

  • Arzhang Cyrus Javan

  • Mark J Giganti

  • Evgenia Aga

  • Michael Gibbs

  • Taylor Cohen

  • Katie Streicher

  • Karina Soboleva

  • Courtney V Fletcher

  • Eric S Daar

  • Alexander L Greninger

  • Robert W Coombs

  • William Fischer

  • Michael D Hughes

  • Davey Smith

  • David Alain Wohl

  • Amy K Barczak

  • Jonathan Z Li

  • for the ACTIV-2/A5401 Study Team

  • September 8, 2025

  • 0 min

Share

Objective:

To evaluate the virologic impact of intramuscular (IM) versus intravenous (IV) administration of tixagevimab/cilgavimab (T/C) in early COVID-19, focusing on viral culture conversion and resistance emergence, with implications for pandemic response.

Key Findings:
  • Both IM and IV administration of T/C achieved rapid elimination of culturable SARS-CoV-2, with implications for reducing transmission.
  • Median time to culture conversion was ≤1.0 day for T/C versus 2.5 days for placebo, highlighting the efficacy of T/C.
  • Minimal emergence of resistance mutations was observed in both treatment groups.
Interpretation:

IM delivery of T/C is a viable alternative to IV administration, offering practical scalability for future viral pandemics while maintaining antiviral efficacy, potentially changing treatment protocols.

Limitations:
  • Study focused on a limited participant group with specific inclusion criteria, which may introduce biases.
  • Further research is needed to assess long-term outcomes and broader population applicability.
Conclusion:

IM administration of T/C provides a rapid and effective treatment option for early COVID-19, with significant implications for scalable therapeutic strategies in pandemics.

Original Source(s)

Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy

  • by Rinki Deo, Manish C Choudhary, Owen T Glover, Rachel Bender Ignacio, Julie Boucau, Kara W Chew, Carlee Moser, Judith S Currier, Joseph J Eron, Arzhang Cyrus Javan, Mark J Giganti, Evgenia Aga, Michael Gibbs, Taylor Cohen, Katie Streicher, Karina Soboleva, Courtney V Fletcher, Eric S Daar, Alexander L Greninger, Robert W Coombs, William Fischer, Michael D Hughes, Davey Smith, David Alain Wohl, Amy K Barczak, Jonathan Z Li, for the ACTIV-2/A5401 Study Team

  • September 8, 2025

Related Content

COVID-19, Vaccines, and Retinal Vascular Disease

A global systematic review of 173 studies found differing associations between COVID-19 infection and vaccination and retinal vascular events, with retinal artery occlusion more common after infection and retinal vein occlusion more common after vaccination.

Long COVID Persistence and Surveillance Gaps Across 58 US Hospitals

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.